BR112022018457A2 - Tratamento de linhas faciais superiores - Google Patents

Tratamento de linhas faciais superiores

Info

Publication number
BR112022018457A2
BR112022018457A2 BR112022018457A BR112022018457A BR112022018457A2 BR 112022018457 A2 BR112022018457 A2 BR 112022018457A2 BR 112022018457 A BR112022018457 A BR 112022018457A BR 112022018457 A BR112022018457 A BR 112022018457A BR 112022018457 A2 BR112022018457 A2 BR 112022018457A2
Authority
BR
Brazil
Prior art keywords
asn
amino acid
acid residue
modified bont
sites
Prior art date
Application number
BR112022018457A
Other languages
English (en)
Portuguese (pt)
Inventor
Grigore Nicolae
Ruffle Katie
Picaut Philippe
Original Assignee
Ipsen Biopharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ipsen Biopharm Ltd filed Critical Ipsen Biopharm Ltd
Publication of BR112022018457A2 publication Critical patent/BR112022018457A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/66—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/91—Injection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Medicinal Chemistry (AREA)
  • Birds (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Massaging Devices (AREA)
  • Percussion Or Vibration Massage (AREA)
BR112022018457A 2020-03-16 2021-03-16 Tratamento de linhas faciais superiores BR112022018457A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB2003813.9A GB202003813D0 (en) 2020-03-16 2020-03-16 Treatment of upper facial lines
PCT/GB2021/050659 WO2021186167A1 (en) 2020-03-16 2021-03-16 Treatment of upper facial lines

Publications (1)

Publication Number Publication Date
BR112022018457A2 true BR112022018457A2 (pt) 2022-11-01

Family

ID=70453766

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022018457A BR112022018457A2 (pt) 2020-03-16 2021-03-16 Tratamento de linhas faciais superiores

Country Status (11)

Country Link
US (2) US20230346674A1 (enExample)
EP (1) EP4120997A1 (enExample)
JP (2) JP2023517727A (enExample)
KR (1) KR20220154739A (enExample)
CN (1) CN115279337A (enExample)
AU (1) AU2021238928A1 (enExample)
BR (1) BR112022018457A2 (enExample)
CA (1) CA3166944A1 (enExample)
GB (1) GB202003813D0 (enExample)
TW (1) TW202140522A (enExample)
WO (1) WO2021186167A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11707510B2 (en) * 2018-02-16 2023-07-25 Preclinics Discovery Gmbh Nucleic acid-based botulinum neurotoxin for therapeutic use
US12011284B2 (en) * 2020-05-19 2024-06-18 Peachy Corp. Systems and methods for preventing and treating wrinkles
GB202206362D0 (en) * 2022-04-29 2022-06-15 Ipsen Biopharm Ltd Treatment of upper facial lines
GB202206361D0 (en) * 2022-04-29 2022-06-15 Ipsen Biopharm Ltd Treatment of a facial dystonia
GB202206348D0 (en) * 2022-04-29 2022-06-15 Ipsen Biopharm Ltd Treatment of limb spasticity
GB202214232D0 (en) 2022-09-28 2022-11-09 Ispen Biopharm Ltd Clostridial neurotoxins comprising an activating exogenous protease cleavage site
GB202214229D0 (en) 2022-09-28 2022-11-09 Ipsen Biopharm Ltd Clostridial neurotoxins comprising an activating endosomal protease cleavage site
WO2025093845A1 (en) * 2023-11-01 2025-05-08 Ipsen Biopharm Limited Use of high dose chimeric botulinum toxin a for the treatment of upper facial lines
AU2023471835A1 (en) * 2023-11-01 2026-04-30 Ipsen Biopharm Limited Use of chimeric botulinum toxin a for treating blepharospasm and hemifacial spasm
GB202318884D0 (en) 2023-12-11 2024-01-24 Ipsen Biopharm Ltd Formulation

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
IL99552A0 (en) 1990-09-28 1992-08-18 Ixsys Inc Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof
US7220422B2 (en) * 2003-05-20 2007-05-22 Allergan, Inc. Methods and compositions for treating eye disorders
DK2154151T3 (da) 2005-09-19 2011-09-05 Allergan Inc Clostridiumtoksinaktiverbare clostridiumtoksiner
EP2524963B1 (en) 2011-05-19 2018-10-31 Ipsen Bioinnovation Limited Methods for the manufacture of proteolytically processed polypeptides
MX359480B (es) 2012-05-30 2018-09-28 President And Fellows Of Harvard College Star Neurotoxina botulínica diseñada.
JP6156954B2 (ja) 2012-11-21 2017-07-05 イプセン バイオイノベーション リミテッド タンパク分解性にプロセシングされたポリペプチドの製造方法
GB201312317D0 (en) * 2013-07-09 2013-08-21 Syntaxin Ltd Cationic neurotoxins
GB201407525D0 (en) 2014-04-29 2014-06-11 Syntaxin Ltd Manufacture of recombinant clostridium botulinum neurotoxins
RU2746736C2 (ru) 2015-03-26 2021-04-20 Президент Энд Феллоуз Оф Гарвард Колледж Сконструированный ботулинический нейротоксин
GB201517450D0 (en) 2015-10-02 2015-11-18 Ipsen Biopharm Ltd Method
GB201607901D0 (en) * 2016-05-05 2016-06-22 Ipsen Biopharm Ltd Chimeric neurotoxins

Also Published As

Publication number Publication date
EP4120997A1 (en) 2023-01-25
GB202003813D0 (en) 2020-04-29
KR20220154739A (ko) 2022-11-22
TW202140522A (zh) 2021-11-01
WO2021186167A1 (en) 2021-09-23
US20230346674A1 (en) 2023-11-02
US20260207462A1 (en) 2026-07-23
JP2026097980A (ja) 2026-06-16
CN115279337A (zh) 2022-11-01
AU2021238928A1 (en) 2022-09-01
JP2023517727A (ja) 2023-04-26
CA3166944A1 (en) 2021-09-23

Similar Documents

Publication Publication Date Title
JP2023517727A5 (enExample)
Gür et al. Effects of low power laser and low dose amitriptyline therapy on clinical symptoms and quality of life in fibromyalgia: a single-blind, placebo-controlled trial
Bellet Diagnosis and treatment of primary focal hyperhidrosis in children and adolescents
DK2489358T3 (en) The oil-extracted product of indigo naturalis and process for their preparation and use
BR112019016585A2 (pt) Uso melhorado da neurotoxina botulínica no tratamento da sialorreia
TORTELLI et al. Effectiveness of acupuncture, ozonio therapy and low-intensity laser in the treatment of temporomandibular dysfunction of muscle origin: a randomized controlled trial
Shipton et al. Trigger point management
Korkmaz et al. Comparison of the efficacy of oxygen-ozone and lidocaine injections in the treatment of myofascial pain syndrome: A randomized clinical trial
Gazerani et al. Site-specific, dose-dependent, and sex-related responses to the experimental pain model induced by intradermal injection of capsaicin to the foreheads and forearms of healthy humans.
Calcutt et al. Protection of sensory function in diabetic rats by Neotrofin
Serra-Añó et al. Immediate effects of a single session of cervical spine manipulation on cervical movement patterns in people with nonspecific neck pain: a randomized controlled trial
Ibraheem Conventional therapy versus positional release technique in the treatment of chronic low back dysfunction
JP2025514278A5 (enExample)
Zhu et al. Clinical efficacy and safety of combined treatment with hyaluronic acid and botulinum toxin type A for reducing facial wrinkles and increases rejuvenation
CN110237229A (zh) 一种减少皮肤色素及治疗疼痛度的中胚层疗法的药物组合物及其制备方法
US20190000937A1 (en) Botulinum toxin for use in the treatment of paratonia
de Abreu Venancio et al. Botulinum toxin, lidocaine, and dry-needling injections in patients with myofascial pain and headaches
KR20230171400A (ko) 보툴리눔 독소 안정화 조성물, 이를 포함하는 보툴리눔 독소 제제 및 이에 사용하기 위한 폴리펩티드
ul Ain et al. Comparative effectiveness of Mobilization with Movement and passive stretching in shoulder impingement syndrome: a randomized controlled trial
JP2024543080A (ja) ボツリヌス毒素組成物
Hegazy et al. Evaluation of botulinum toxin injection in masticatory muscles for managing temporomandibular disorders pain.
Ly et al. Effect of laser acupuncture combine a knee exercise on patients with knee osteoarthritis: a pilot trial
Abdullatif et al. Effect of high intensity laser therapy on the range of motion of facial muscles in patients with Chronic Bell’s Palsy
Akulov et al. Five-year follow-up after neurosurgery complicated by facial neuropathy
Putra et al. The Effect of Electroacupuncture and Gua Sha on Reducing Pain Scale and Neck Disability in Neck Pain Cases at Siligita Husada Independent Acupuncture Practice

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]